Melanotan 2 vs PT-141: Melanocortin Receptor Research

Melanotan 2 (MT-2) and PT-141 (bremelanotide) are both melanocortin-receptor agonists, but receptor selectivity makes them functionally different research tools. MT-2 is a broad-spectrum agonist; PT-141 is a metabolite of MT-2 optimised for MC4R activity. This comparison summarises the published literature relevant to laboratory research.

At-a-glance comparison

| Attribute | Melanotan 2 | PT-141 (Bremelanotide) | |---|---|---| | Class | Cyclic alpha-MSH analog | Cyclic alpha-MSH analog (MT-2 metabolite) | | Receptor profile | MC1R, MC3R, MC4R, MC5R (broad) | MC3R, MC4R (selective) | | Primary research focus | Pigmentation (MC1R), CNS effects (MC4R) | CNS sexual-behavior models (MC4R) | | Half-life | ~33 hours (extended) | ~2 hours (parent); active metabolite longer | | Regulatory status | Research only | FDA-approved (Vyleesi) for HSDD | | Pigmentation effect | Yes (MC1R activity) | Minimal (no MC1R activity) |

Mechanism — receptor selectivity drives the difference

Both peptides are cyclic analogs of native alpha-MSH. MT-2 retains agonism at MC1R (melanocyte pigmentation) in addition to central MC3R/MC4R activity, which is why pigmentation darkening is consistently reported in MT-2 research models. PT-141 lacks meaningful MC1R activity, so pigmentation changes are not a primary finding in PT-141 literature.

Published research highlights

• MT-2 was developed at the University of Arizona to study photoprotection via MC1R-mediated melanogenesis.
• PT-141 emerged from the same program when researchers noticed CNS sexual-behavior effects independent of pigmentation — those effects map to central MC4R.
• PT-141 (bremelanotide) was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women, validating the MC4R mechanism in humans.

Pharmacokinetics

MT-2 has an extended half-life (~33 hours) producing prolonged receptor occupancy useful for chronic-exposure pigmentation studies. PT-141 has a shorter pharmacokinetic profile better suited to acute behavioral endpoints.

Side-effect spectrum in published research

Both peptides share melanocortin-class effects: nausea, flushing, transient blood-pressure elevation, and yawning/stretching reflex. MT-2 additionally drives pigmentation, nevus darkening, and appetite suppression — the latter via MC4R hypothalamic activity shared with PT-141.

Frequently asked research questions

Why does MT-2 darken skin but PT-141 doesn't? MC1R drives melanocyte activation. MT-2 is a broad agonist that hits MC1R; PT-141's structural changes removed meaningful MC1R activity.

Is PT-141 just a cleaner MT-2? Functionally for CNS sexual-behavior research, yes — PT-141 isolates MC4R effects without confounding pigmentation changes.

Which has more published clinical data? PT-141 (bremelanotide) has the larger clinical dataset due to FDA approval as Vyleesi; MT-2 remains pre-clinical/research-only.

Related research

• PT-141 mechanism overview
• Melanotan 2 pigmentation research
• Melanocortin receptor pharmacology